ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Japan’s Astellas Pharma has agreed to buy Iveric Bio, a developer of treatments for retinal diseases, for about $5.9 billion. Iveric’s lead product is avacincaptad pegol, a protein inhibitor that may slow the progression of geographic atrophy, an advanced form of age-related macular degeneration. The US Food and Drug Administration accepted Iveric’s new drug application for the molecule in February, and Astellas expects a decision on it by Aug. 19.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter